Home> Products> renal dysfunction

{ "products": [ { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-10-02T11:20:20.402Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6810aa8d5a26e4010ea41a99", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH MET", "description": "EMPATECH MET 12.5/500 is a powerful oral antidiabetic combination therapy containing Empagliflozin and Metformin Hydrochloride, designed to manage Type 2 Diabetes Mellitus effectively. This dual-action formula helps control blood sugar levels, supports weight management, and offers added cardiovascular benefits. EMPATECH MET 12.5/500 is particularly beneficial for adults who require a second-line treatment when diet, exercise, and monotherapy are not sufficient.\n\nKey Ingredients\nEmpagliflozin (12.5 mg):\nA sodium-glucose co-transporter-2 (SGLT2) inhibitor that helps reduce blood glucose levels by promoting glucose excretion through urine.\n\nMetformin Hydrochloride (500 mg):\nA biguanide class medication that lowers blood glucose by improving insulin sensitivity and reducing glucose production in the liver.\n\nKey Benefits\nHelps in lowering and maintaining stable blood glucose levels\n\nPromotes weight loss and reduces visceral fat\n\nReduces the risk of cardiovascular complications in diabetic patients\n\nSupports renal protection in people with diabetes and mild kidney dysfunction\n\nOffers a low risk of hypoglycemia compared to some other therapies\n\nImproves glycemic control with a dual mechanism of action\n\nHow Does It Work?\nEMPATECH MET 12.5/500 functions through two complementary mechanisms:\n\nEmpagliflozin works by blocking SGLT2 proteins in the kidneys, reducing the reabsorption of glucose and increasing its excretion via urine. This lowers blood sugar levels independently of insulin action.\n\nMetformin acts primarily by inhibiting hepatic glucose production and improving the body’s sensitivity to insulin, allowing for better uptake and usage of glucose by muscles and fat tissues.\n\nTogether, they provide a comprehensive glycemic control strategy, especially for patients not responding well to monotherapy.\n\nDirections for Use\nTake the tablet as prescribed by your doctor, usually once or twice daily with meals.\n\nSwallow the tablet whole with water; do not crush or chew.\n\nContinue following a healthy diet and regular exercise routine for optimal results.\n\nMonitor blood sugar levels regularly and report any unusual changes to your healthcare provider.\n\nDo not stop the medication without medical advice, even if your blood sugar levels improve.\n\nSide Effects\nCommon Side Effects:\n\nIncreased urination\n\nThirst or dry mouth\n\nNausea or mild gastrointestinal upset\n\nHeadache\n\nFatigue\n\nLess Common but Serious Side Effects:\n\nRisk of urinary tract infections or genital infections\n\nLactic acidosis (rare but serious; associated with Metformin)\n\nDehydration or low blood pressure, especially in elderly patients\n\nElectrolyte imbalances\n\nSeek immediate medical help if you experience severe abdominal pain, muscle cramping, breathing difficulties, or unusual tiredness.", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "unusual tiredness", "medical advice", "monotherapy directions", "healthcare provider", "healthy diet", "chew continue", "meals swallow", "fat tissues", "dual mechanism", "hypoglycemia compared", "cardiovascular complications", "secondline treatment", "metformin dehydration", "insulin allowing", "bodys sensitivity", "kidneys reducing", "low risk", "diet exercise", "improving insulin sensitivity", "promoting glucose excretion", "reducing glucose production", "side effects risk", "biguanide class medication", "lowers blood glucose", "low blood pressure", "regular exercise routine", "metformin hydrochloride designed", "urinary tract infections", "dry mouth nausea", "blocking sglt2 proteins" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2093, "imageuri": "https://productimages.withfloats.com/actual/6810aa8f5c4a4ba3d41a8c35.png", "tileimageuri": "https://productimages.withfloats.com/tile/6810aa8f5c4a4ba3d41a8c35.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-04-29T10:31:41.504Z", "updatedon": "2025-04-29T10:32:46.171Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-met/2093", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin (12.5mg) ,Metformin Hydrochloride (500mg)", "category": "DIABETIC RANGE", "tags": [ "empagliflozin 12.5 mg+metformin 500 mg price", "empagliflozin 12.5 mg+metformin 1000 mg", "empagliflozin 12.5mg brands in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e7ff07e47881008f6860e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIMETAZ CR 80 ", "description": "TRIMETAZ CR 80 \nTrimetazidine (80mg)\nIntroduction\nTRIMETAZ CR 80 is a medication containing Trimetazidine hydrochloride, formulated to treat angina pectoris and certain other cardiovascular conditions. It is known for its metabolic effects on the heart muscle, improving myocardial efficiency and reducing symptoms associated with ischemic heart disease.\n\nComposition\n\nTrimetazidine (80mg): The active ingredient, Trimetazidine, acts as a cellular metabolic agent that enhances myocardial glucose utilization and improves energy production in the heart muscle.\nMechanism of Action\nTrimetazidine exerts its therapeutic effects through several mechanisms:\n\nMetabolic Regulation: Shifts myocardial energy substrate utilization from fatty acids toward glucose oxidation, which is more efficient and requires less oxygen.\nAnti-ischemic Effect: Protects the heart against ischemic damage by preserving cellular energy metabolism and reducing oxidative stress.\nImprovement in Symptomatology: Reduces angina symptoms such as chest pain, shortness of breath, and exercise intolerance by enhancing myocardial function.\nIndications\nTRIMETAZ CR 80 is indicated for:\n\nChronic Stable Angina Pectoris: Used as adjunctive therapy in patients who are inadequately controlled with other anti-anginal medications.\nIschemic Heart Disease: Helps improve myocardial function and reduce symptoms associated with coronary artery disease.\nDosage and Administration\n\nThe usual dosage of TRIMETAZ CR 80 is one tablet (80mg) taken orally twice daily, preferably with meals.\nThe extended-release formulation ensures sustained therapeutic levels of Trimetazidine throughout the day.\nDosage adjustments may be necessary based on individual patient response and tolerance.\nSide Effects\nCommon side effects may include:\n\nHeadache\nDizziness\nNausea\nGastrointestinal disturbances (such as abdominal pain or diarrhea)\nSevere side effects are rare but may include:\n\nAllergic reactions (rash, itching, swelling)\nExtrapyramidal symptoms (involuntary movements)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with severe renal impairment or hepatic dysfunction, as Trimetazidine metabolism may be altered.\nMonitor patients for signs of extrapyramidal symptoms, especially in patients with Parkinson's disease or other movement disorders.\nAvoid abrupt discontinuation of Trimetazidine, as it may worsen angina symptoms.\nDrug Interactions\n\nTrimetazidine may interact with other medications that affect myocardial metabolism or cardiac function, including beta-blockers and calcium channel blockers. Close monitoring is recommended when used concomitantly.\nConclusion\nTRIMETAZ CR 80 is a valuable therapeutic option for managing chronic stable angina pectoris and ischemic heart disease by improving myocardial efficiency and reducing symptoms associated with cardiac ischemia. Its mechanism of action, focusing on metabolic modulation and anti-ischemic effects, makes it an effective adjunctive therapy in patients with inadequate symptom control on standard anti-anginal medications. Proper dosage, administration, and monitoring for side effects are essential to ensure safe and effective use of TRIMETAZ CR 80 in cardiovascular patients. Consultation with a healthcare provider is recommended for personalized treatment plans and management of cardiac conditions with TRIMETAZ CR 80.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 435.0, "discountamount": 130.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "one tablet", "chest pain", "less oxygen", "fatty acids", "TRIMETAZ CR", "usual dosage", "heart muscle", "Proper dosage", "effective use", "abdominal pain", "angina symptoms", "ischemic damage", "Close monitoring", "cardiac ischemia", "oxidative stress", "cardiac function", "Drug Interactions", "active ingredient", "glucose oxidation", "metabolic effects", "energy production", "other medications", "Dosage adjustments", "Allergic reactions", "adjunctive therapy", "several mechanisms", "cardiac conditions", "healthcare provider", "Hepatic dysfunction", "myocardial function", "therapeutic effects", "Severe side effects", "Common side effects", "metabolic modulation", "Metabolic Regulation", "liver function tests", "involuntary movements", "anti-ischemic effects", "myocardial efficiency", "myocardial metabolism", "abrupt discontinuation", "ischemic heart disease", "Extrapyramidal symptoms", "cardiovascular patients", "coronary artery disease", "severe renal impairment", "Trimetazidine metabolism", "cellular metabolic agent", "other movement disorders", "calcium channel blockers", "cellular energy metabolism", "inadequate symptom control", "Trimetazidine hydrochloride", "valuable therapeutic option", "individual patient response", "extended-release formulation", "sustained therapeutic levels", "personalized treatment plans", "Gastrointestinal disturbances", "other anti-anginal medications", "myocardial glucose utilization", "Chronic Stable Angina Pectoris", "other cardiovascular conditions", "standard anti-anginal medications", "myocardial energy substrate utilization" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1938, "imageuri": "https://productimages.withfloats.com/actual/668e7ff3f07c99c3af8e8504.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e7ff3f07c99c3af8e8504.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:34:56.538Z", "updatedon": "2024-07-10T12:34:56.538Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trimetaz-cr-80-/1938", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIMETAZ CR 80 ", "category": "CARDIOLOGYRANGE", "tags": [ "Trimetazidine 80mg price", "Trimetazidine 35 mg uses", "Trimetazidine 80 mg brand name", "When to stop taking trimetazidine", "Trimetazidine hydrochloride extended release CAPSU", "Trimetazidine mechanism of action", "Trimetazidine 35 mg brand name", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e670cc6d2d31770978860", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "CEFEXOTIME DICLOXA ", "description": "CEFEXOTIME DICLOXA \nCefixime (200mg), Dicloxacillin ER (500mg)\nIntroduction\nCEFEXOTIME DICLOXA is a potent antibiotic combination therapy that includes Cefixime (200mg) and Dicloxacillin ER (500mg). This medication is designed to combat a broad spectrum of bacterial infections, leveraging the synergistic effects of both antibiotics to enhance efficacy.\n\nComposition\n\nCefixime (200mg): A third-generation cephalosporin antibiotic known for its broad-spectrum activity against Gram-positive and Gram-negative bacteria. It works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death.\nDicloxacillin ER (500mg): An extended-release form of dicloxacillin, a penicillinase-resistant penicillin. It is particularly effective against penicillinase-producing staphylococci and works by inhibiting cell wall synthesis.\nMechanism of Action\n\nCefixime: It binds to penicillin-binding proteins (PBPs) within the bacterial cell wall, disrupting the cross-linking of peptidoglycan chains necessary for cell wall strength and rigidity, resulting in cell lysis.\nDicloxacillin: It similarly binds to PBPs, preventing the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, which is crucial for maintaining cell wall integrity.\nIndications\nCEFEXOTIME DICLOXA is indicated for the treatment of various bacterial infections, including:\n\nRespiratory tract infections (e.g., bronchitis, pneumonia)\nUrinary tract infections (UTIs)\nSkin and soft tissue infections\nOtitis media\nSinusitis\nBone and joint infections\nDosage and Administration\nThe typical dosage for adults is one tablet taken twice daily, with or without food. The duration of treatment depends on the severity and type of infection, usually ranging from 7 to 14 days. It is essential to complete the full course of therapy to prevent the development of antibiotic-resistant bacteria.\n\nSide Effects\nCommon side effects may include:\n\nGastrointestinal disturbances (nausea, vomiting, diarrhea)\nAllergic reactions (rash, itching, anaphylaxis in severe cases)\nPseudomembranous colitis\nHepatic dysfunction (elevated liver enzymes)\nHematologic effects (eosinophilia, neutropenia)\nRenal toxicity (in rare cases)\nPrecautions\n\nAllergy: Patients with a history of allergic reactions to cephalosporins, penicillins, or any other beta-lactam antibiotics should use this medication with caution.\nRenal Impairment: Dose adjustment may be necessary for patients with renal dysfunction.\nPregnancy and Lactation: The safety of this medication in pregnant and breastfeeding women has not been fully established. It should only be used if clearly needed and prescribed by a healthcare provider.\nDrug Interactions\n\nProbenecid: May increase blood levels of Cefixime.\nWarfarin: Concomitant use can enhance anticoagulant effects, increasing the risk of bleeding.\nMethotrexate: Cefixime may reduce renal clearance of methotrexate, increasing its toxicity.\nOral Contraceptives: Antibiotics may reduce the efficacy of oral contraceptives, suggesting the need for additional contraceptive measures.\nConclusion\nCEFEXOTIME DICLOXA, with its combination of Cefixime and Dicloxacillin, provides a robust treatment option for various bacterial infections. Its broad-spectrum efficacy, combined with the extended-release formulation, ensures a potent and convenient antibiotic therapy. As with all antibiotics, it is crucial to use this medication as prescribed and complete the full course to prevent the emergence of resistant bacteria and achieve optimal therapeutic outcomes. Always consult with a healthcare professional before starting any new medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 395.0, "discountamount": 118.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "rare cases", "one tablet", "cell lysis", "full course", "blood levels", "severe cases", "7 to 14 days", "Otitis media", "new medication", "Renal toxicity", "typical dosage", "broad spectrum", "renal clearance", "Concomitant use", "Dose adjustment", "Dicloxacillin ER", "Renal Impairment", "joint infections", "Drug Interactions", "renal dysfunction", "Allergic reactions", "CEFEXOTIME DICLOXA", "cell wall strength", "Oral Contraceptives", "healthcare provider", "breastfeeding women", "Hepatic dysfunction", "Hematologic effects", "synergistic effects", "Common side effects", "cell wall integrity", "peptidoglycan chains", "bacterial cell walls", "extended-release form", "anticoagulant effects", "Gram-negative bacteria", "soft tissue infections", "elevated liver enzymes", "broad-spectrum efficacy", "healthcare professional", "broad-spectrum activity", "peptidoglycan synthesis", "robust treatment option", "Pseudomembranous colitis", "Urinary tract infections", "penicillin-binding proteins", "final transpeptidation step", "Respiratory tract infections", "various bacterial infections", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "antibiotic-resistant bacteria", "other beta-lactam antibiotics", "convenient antibiotic therapy", "bacterial cell wall synthesis", "additional contraceptive measures", "penicillinase-resistant penicillin", "penicillinase-producing staphylococci", "potent antibiotic combination therapy", "third-generation cephalosporin antibiotic" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1928, "imageuri": "https://productimages.withfloats.com/actual/668e670f4e0af60ab3e5e128.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e670f4e0af60ab3e5e128.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T10:48:44.065Z", "updatedon": "2024-07-10T10:48:44.065Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/cefexotime-dicloxa-/1928", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CEFEXOTIME DICLOXA ", "category": "GENERAL RANGE", "tags": [ "Cefixime and Dicloxacillin tablets Uses in Hindi", "Cefixime+Dicloxacillin er tablets", "", "Cefixime and Dicloxacillin uses", "Cefixime Dicloxacillin and lactic acid bacillus ta", "", "Cefixime + Dicloxacillin and Lactic acid bacillus ", "Cefixime Dicloxacillin mr and lactic acid bacillus", "Cefixime and Dicloxacillin tablets side effects", "Cefixime dicloxacillin tablet uses in tamil" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68c29ba02244c906e7790e2b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TELAVINCE 300", "description": "TELAVINCE 300 is a high-quality antiviral medication containing Tenofovir Disoproxil Fumarate 300 mg, specifically formulated for the effective management of HIV-1 infection and chronic Hepatitis B in adults and adolescents. Manufactured under strict pharmaceutical standards, TELAVINCE 300 offers consistent, potent, and clinically proven antiviral action, helping to suppress viral replication and improve immune function.\n\nTenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor (NtRTI). It works by interfering with the enzyme reverse transcriptase, which is essential for viral replication in HIV and Hepatitis B viruses. By inhibiting this enzyme, TELAVINCE 300 reduces the amount of virus in the body, helping to prevent further immune system damage and liver complications.\n\n \nKey Indications:\n \n\nTELAVINCE 300 is indicated for:\n\nHIV-1 Infection: In combination with other antiretroviral agents for the treatment of HIV-1 in adults and adolescents (aged 12 years and older, weighing at least 35 kg).\n\nChronic Hepatitis B: For the treatment of chronic hepatitis B virus infection in adults and adolescents with compensated liver disease and evidence of active viral replication.\n\n \nMechanism of Action:\n \nTenofovir Disoproxil Fumarate is a prodrug of tenofovir, which, once absorbed and metabolized in the body, is converted into tenofovir diphosphate, the active form. Tenofovir diphosphate acts as a competitive inhibitor of reverse transcriptase, incorporating itself into the viral DNA chain and causing premature chain termination. This process disrupts the life cycle of the virus, significantly reducing its ability to multiply and spread.\n\n \nDosage and Administration:\n \n\nRecommended Dose for Adults and Adolescents (≥12 years, ≥35 kg): One tablet (300 mg) once daily, preferably with food.\n\nFor HIV Treatment: Administer in combination with other antiretroviral medications as per the treatment regimen.\n\nFor Chronic Hepatitis B: Monotherapy or as part of combination therapy, depending on patient condition and physician's assessment.\n\nDosage adjustments may be required in patients with renal impairment. Close monitoring is recommended for patients with existing kidney disease.\n\n \nKey Benefits of TELAVINCE 300:\n \n\nPotent Antiviral Action: Rapid and sustained suppression of HIV and HBV replication.\nOnce-Daily Dosing: Improves patient compliance and treatment adherence.\n\nBacked by Clinical Research: Proven efficacy in managing viral load and improving immune markers (CD4 count).\n\nTrusted Quality: Manufactured under GMP-certified facilities with stringent quality control processes.\n\nPart of First-Line Therapy: Recommended in various national and international treatment guidelines for HIV and Hepatitis B.\n\n \nSafety and Precautions:\n \n\nRenal Monitoring: Tenofovir may affect kidney function. Routine renal function tests are recommended before and during treatment.\n\nBone Mineral Density: Long-term use may reduce bone mineral density. Consider monitoring in patients at risk of osteopenia or osteoporosis.\n\nHepatic Flare: Discontinuation of therapy in hepatitis B patients may result in severe acute exacerbations. Liver function should be closely monitored post-treatment.\n\nLactic Acidosis and Hepatomegaly: Rare but serious side effects. Patients presenting symptoms such as abdominal pain, fatigue, or difficulty breathing should seek immediate medical attention.\n\n \n\nPossible Side Effects:\n \n\nMost patients tolerate TELAVINCE 300 well. However, some may experience:\n\nNausea\n\nDiarrhea\n\nHeadache\n\nFatigue\n\nRash\n\nDizziness\n\nDecreased bone mineral density\n\nRenal impairment (in rare cases)\n\nIf any side effects persist or worsen, consult a healthcare professional immediately.\n\n \nStorage Instructions:\n \n\nStore in a cool, dry place below 30°C.\n\nProtect from light and moisture.\n\nKeep out of reach of children.\n\n \n\nWhy Choose TELAVINCE 300?\n \n\nTELAVINCE 300 offers a dependable, clinically validated solution for the long-term management of HIV and Hepatitis B. With its once-daily dosing and proven effectiveness, TELAVINCE 300 is an ideal choice for patients and healthcare providers looking for quality, safety, and therapeutic reliability. It is manufactured by a trusted name in healthcare, ensuring every tablet meets global pharmaceutical standards.\n\n \nDisclaimer:\n \n\nThis product description is for informational purposes only and is not a substitute for professional medical advice. Always consult your doctor or healthcare provider before starting any medication.", "price": 1480.0, "discountamount": 444.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2179, "imageuri": "https://productimages.withfloats.com/actual/68c29ba3794abb27ab248d73.png", "tileimageuri": "https://productimages.withfloats.com/tile/68c29ba3794abb27ab248d73.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-11T09:51:28.508Z", "updatedon": "2025-09-11T09:51:28.508Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/telavince-300/2179", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Tenofovir Disoproxil Fumarate Tablets ip 300 mg", "category": "GENERAL RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b02a01f5434d48fca8b8e5", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "BETHNEVOID 50", "description": "BETHNEVOID 50 contains Bethanechol Chloride 50 mg, a cholinergic agonist (parasympathomimetic) that helps stimulate bladder muscle contractions. By directly activating muscarinic receptors in the bladder, it improves urinary flow and assists patients struggling with urinary retention. This makes it especially useful for individuals experiencing difficulty in passing urine due to conditions like post-surgical recovery, postpartum complications, or certain bladder dysfunctions.\n\nThe action of Bethanechol enhances bladder tone, ensuring more effective emptying of urine and reducing the discomfort associated with incomplete bladder evacuation.\n\nUses of BETHNEVOID 50\n\nUrinary Retention Management – Assists patients who are unable to empty their bladder properly.\n\nPost-Surgical Retention – Restores smooth urination after procedures or anesthesia.\n\nNeurogenic Bladder Disorders – Beneficial for those with weak bladder muscles caused by nerve dysfunction.\n\nEnhanced Bladder Emptying – Reduces urinary stasis and lowers the risk of urinary tract infections (UTIs).\n\nSide Effects of BETHNEVOID 50\n\nLike all medicines, BETHNEVOID 50 may cause certain side effects, ranging from mild to less common but serious reactions.\n\nCommon Side Effects:\n\nAbdominal discomfort or cramps\n\nNausea and vomiting\n\nLoose stools (diarrhea)\n\nExcess salivation or sweating\n\nHeadache\n\nLess Common but Serious Side Effects:\n\nLow blood pressure (hypotension)\n\nDizziness or flushing\n\nBreathing difficulties (especially in asthma patients)\n\nIrregular or fast heartbeat\n\nUrinary urgency or overactivity\n\nSeek immediate medical attention if severe symptoms occur.\n\nPrecautions Before Taking BETHNEVOID 50\n\nNot for Obstructive Conditions – Should not be used if urinary obstruction or bladder stones are present.\n\nAsthma or COPD Patients – May aggravate respiratory issues.\n\nCardiac Concerns – Use with caution in individuals with heart disease, peptic ulcers, or low blood pressure.\n\nPregnancy & Breastfeeding – Only under medical advice.\n\nDriving & Alertness – May cause dizziness; avoid driving until the effect is known.\n\nDrug Interactions with BETHNEVOID 50\n\nOther Cholinergic Drugs – May intensify cholinergic side effects.\n\nAnticholinergics (e.g., Atropine, Hyoscyamine) – Can reduce Bethanechol’s effectiveness.\n\nBlood Pressure Medications – Risk of further lowering blood pressure.\n\nBronchoconstrictors – Can worsen respiratory problems if taken together.\n\nConclusion\n\nBETHNEVOID 50 (Bethanechol Chloride 50 mg Tablets) is an effective treatment for urinary retention and bladder dysfunction. By improving bladder muscle contractions, it ensures smoother urination, reduces infection risks, and enhances overall quality of life.\n\nWhen used under proper medical guidance, BETHNEVOID 50 is a reliable choice for patients recovering from surgery or dealing with neurogenic bladder conditions.", "price": 225.0, "discountamount": 67.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2168, "imageuri": "https://productimages.withfloats.com/actual/68b02a049f24dedaddb226a2.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b02a049f24dedaddb226a2.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T10:05:53.188Z", "updatedon": "2025-08-28T10:22:32.936Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/bethnevoid-50/2168", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Bethanechol Chloride 50 mg", "category": "UROLOGYRANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68b0285a8456f6cd1a658352", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ALFUGEM T 5/10", "description": "ALFUGEM T 5/10 is a uniquely formulated combination of Alfuzosin Hydrochloride ER and Tadalafil, created to manage two common male health concerns—benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). This dual-benefit tablet not only helps relieve urinary symptoms caused by an enlarged prostate but also enhances sexual performance by improving blood flow to penile tissues.\n\nAlfuzosin, an alpha-1 adrenergic blocker, works by relaxing the smooth muscles of the prostate and bladder neck, allowing for easier urine flow. On the other hand, Tadalafil, a PDE5 inhibitor, relaxes blood vessels and supports better erections during sexual activity. Together, they offer a holistic treatment option for men dealing with both prostate-related urinary difficulties and sexual health concerns.\n\nUses of ALFUGEM T 5/10\n\nBenign Prostatic Hyperplasia (BPH): Eases urinary issues such as weak stream, frequent urination, incomplete bladder emptying, and difficulty initiating urination.\n\nErectile Dysfunction (ED): Improves erectile quality and sexual satisfaction.\n\nDual Therapy: Provides relief for men suffering from both BPH and ED, minimizing the need for multiple medications.\n\nEnhanced Quality of Life: Restores comfort, confidence, and overall wellness by improving both urinary and sexual functions.\n\nSide Effects of ALFUGEM T 5/10\n\nLike most medications, ALFUGEM T 5/10 may cause side effects, usually mild and temporary as the body adapts to treatment.\n\nCommon side effects include:\n\nHeadache\n\nDizziness or lightheadedness\n\nNasal congestion\n\nBack pain\n\nFlushing\n\nLess common but serious side effects:\n\nSudden low blood pressure (hypotension)\n\nSevere dizziness or fainting\n\nProlonged, painful erections (priapism – requires urgent care)\n\nVision or hearing disturbances\n\nAllergic reactions (rash, itching, facial/lip/throat swelling)\n\nPrecautions Before Use\n\nHeart Problems: Patients with recent heart attack, stroke, or serious heart disease should only use under strict medical advice.\n\nBlood Pressure: May lower blood pressure—avoid combining with other strong antihypertensives unless prescribed.\n\nNitrate Warning: Must not be used with nitrate medications (for chest pain/angina) due to risk of severe hypotension.\n\nLiver or Kidney Impairment: Dose adjustments may be needed.\n\nAlertness: Can cause dizziness—avoid driving or operating heavy machinery until you know your body’s response.\n\nDrug Interactions\n\nALFUGEM T 5/10 may interact with other medicines:\n\nNitrates (Nitroglycerin, Isosorbide): Can lead to life-threatening hypotension.\n\nAntihypertensives: May intensify blood pressure-lowering effects.\n\nOther PDE5 inhibitors (Sildenafil, Vardenafil): Should not be combined.\n\nStrong CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir): May increase Alfuzosin or Tadalafil levels.\n\nAlcohol: Increases dizziness and risk of low blood pressure.\n\nConclusion\n\nALFUGEM T 5/10 (Alfuzosin Hydrochloride ER & Tadalafil Tablets) is a comprehensive dual-action therapy designed for men experiencing both urinary issues due to BPH and sexual challenges related to ED. By combining an effective alpha-blocker with a proven PDE5 inhibitor, it provides relief from urinary discomfort while restoring erectile performance and confidence.\n\nWith proper medical guidance, ALFUGEM T 5/10 can greatly improve overall quality of life, making it a reliable option for men seeking urological and sexual wellness in a single solution.", "price": 385.0, "discountamount": 115.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2167, "imageuri": "https://productimages.withfloats.com/actual/68b0285da77b30c98906ef23.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b0285da77b30c98906ef23.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:58:50.008Z", "updatedon": "2025-08-28T09:58:50.008Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/alfugem-t-5-10/2167", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Alfuzosin Hydrochloride ER & Tadalafil Tablets", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6891f29bfb7044dfb2d43adf", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "MAGRAL 160", "description": "MAGRAL 160 is a pharmaceutical medication containing megestrol acetate 160 mg, a synthetic progestin known for its potent antineoplastic and appetite-stimulating properties. This drug is primarily prescribed to manage significant health challenges such as unexplained weight loss, anorexia, and cachexia, especially in patients suffering from chronic conditions like cancer or AIDS. Additionally, megestrol acetate functions as a hormone therapy agent employed in the treatment of certain hormone-sensitive malignancies. Its dual action both supports tumor management and improves patients' nutritional status by stimulating appetite and promoting weight gain, thereby enhancing overall quality of life. The drug is regarded as a crucial option in oncology and palliative care for managing complex conditions related to hormone-dependent cancers and severe wasting syndromes.\n\nWhat is MAGRAL 160?\nMAGRAL 160 is an oral medication formulated with megestrol acetate 160 mg, a synthetic progestin hormone derivative. It works primarily by modulating hormone receptors and altering hormone levels that influence the growth of hormone-responsive tumors such as breast and endometrial cancers. Apart from its antineoplastic action, it stimulates appetite by acting on the hypothalamic centers responsible for hunger, helping patients suffering from severe weight loss regain a healthy appetite and weight.\n\nUses of MAGRAL 160\n\nTo treat hormone-dependent cancers, specifically advanced breast cancer and endometrial cancer.\n\nTo stimulate appetite and promote weight gain in patients experiencing anorexia, cachexia, or unexplained severe weight loss related to chronic illnesses like cancer or AIDS.\n\nTo manage wasting syndromes that lead to malnutrition and significant weight loss.\n\nTo serve as an antineoplastic agent in hormone-sensitive malignancies.\n\nIn short, MAGRAL 160 is primarily used to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy.\n\nSide Effects of MAGRAL 160\n\nWeight gain (often desirable but can be excessive)\n\nFluid retention and edema (swelling)\n\nNausea and vomiting\n\nDiarrhea or constipation\n\nVaginal bleeding or spotting in women\n\nFatigue, weakness, and insomnia\n\nHeadache and dizziness\n\nIncreased risk of blood clots (deep vein thrombosis or pulmonary embolism)\n\nHormonal imbalances, such as decreased sex hormone levels, which can lead to sexual dysfunction or bone density loss\n\nAllergic reactions including rash or itching\n\nPatients should report severe or unusual symptoms, especially signs of blood clots such as limb swelling, chest pain, or sudden shortness of breath, immediately to their healthcare provider.\n\nPrecautions before Using MAGRAL 160\n\nInform your doctor if you are pregnant, breastfeeding, or planning to conceive as MAGRAL 160 is contraindicated in pregnancy.\n\nDisclose any history of blood clots, cardiovascular diseases, liver or kidney impairment.\n\nPatients with diabetes should monitor blood sugar closely as megestrol acetate may cause hyperglycemia.\n\nAvoid sudden discontinuation without medical advice to prevent potential hormonal withdrawal effects.\n\nRegular monitoring is required, including hormone levels and blood tests, to assess efficacy and safety during treatment.\n\nUse cautiously in patients at risk for deep vein thrombosis or pulmonary embolism due to increased clotting risks.\n\nDrug Interactions: What Drugs Interact with MAGRAL 160?\n\nCYP3A4 enzyme inducers (e.g., rifampin, phenytoin) may reduce the effectiveness of megestrol acetate by increasing its metabolism.\n\nConcurrent use with blood thinners (anticoagulants) requires careful monitoring as MAGRAL 160 might influence clotting parameters.\n\nCombining with drugs that affect hormonal pathways, such as other hormonal therapies or corticosteroids, may alter treatment outcomes.\n\nInteractions with diabetes medications might necessitate dose adjustment due to potential effects on blood sugar control.\n\nCareful medical supervision is necessary when used with immunosuppressants or other chemotherapy agents to avoid additive side effects or altered drug levels.\n\nConclusion\nMAGRAL 160, containing megestrol acetate 160 mg, is a clinically validated medication widely used to manage complex conditions such as hormone-dependent cancers as well as severe weight loss due to anorexia and cachexia. Its unique ability to act both as an antineoplastic agent and an appetite stimulant makes it invaluable in improving patient outcomes, nutritional status, and overall quality of life. Patients prescribed MAGRAL 160 should adhere strictly to their healthcare provider’s instructions and report any adverse effects promptly. This medication should always be used under medical supervision to ensure optimal benefits and minimize risks.", "price": 810.0, "discountamount": 243.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2156, "imageuri": "https://productimages.withfloats.com/actual/6891f2a0115b51057b971998.png", "tileimageuri": "https://productimages.withfloats.com/tile/6891f2a0115b51057b971998.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-05T12:01:31.195Z", "updatedon": "2025-08-05T12:01:31.195Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/magral-160/2156", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "megestrol acetate 160 mg", "category": "Gynaecology", "tags": [ "megestrol acetate 160 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }